Loading
A phase 3 trial testing Quemliclustat in pancreatic ductal adenocarcinoma, active and no longer recruiting.
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma is a phase 3 interventional study registered as NCT06608927, led by Arcus Biosciences with Taiho Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Randomised, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma. Planned enrolment is 610 participants (estimated). The study started in 2024-12-13 and primary completion is expected in 2030-11-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Quemliclustat, Arcus Biosciences, CD73 / adenosine axis.
Shares Arcus Biosciences, CD73 / adenosine axis.
Shares Quemliclustat, CD73 / adenosine axis.
Shares CD73 / adenosine axis, Pancreatic ductal adenocarcinoma.
Shares CD73 / adenosine axis, Pancreatic ductal adenocarcinoma.
Shares CD73 / adenosine axis, Pancreatic ductal adenocarcinoma.
Shares CD73 / adenosine axis, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares CD73 / adenosine axis, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/